Program
Moxifloxacin
Also written as “Avelox (Moxifloxacin, BAY12-8039)”, “Moxifloxacin (Avelox, BAY12-8039)” and “moxifloxacin”.
Its studies are mostly in Cataract · Conjunctivitis, Bacterial · Otitis Media · Sinusitis · Community-Acquired Pneumonia, led by 14 companies.
Drug pageMoxifloxacin: every studyMany companies study it; this page follows only the 55 they lead. All 201 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayerits history only | 200 open or running | phase 4since Jun 26, 2007 | Nov 21, 2006 | none ahead |
| Alcon | 140 open or running | phase 4since Apr 4, 2006 | Apr 4, 2006 | none ahead |
| Pfizerits history only | 40 open or running | phase 1since Jul 10, 2007 | Jul 10, 2007 | none ahead |
| GlaxoSmithKlineits history only | 30 open or running | phase 1since Oct 8, 2009 | Oct 8, 2009 | none ahead |
| Da Volterraits history only | 20 open or running | phase 1since Jun 25, 2014 | Jun 25, 2014 | none ahead |
| Laboratorios Sophia S.A de C.V.its history only | 21 open or running | phase 3since Jul 30, 2025 | Apr 9, 2024 | none ahead |
| Richmond Pharmacologyits history only | 20 open or running | phase 1since Jun 19, 2012 | Jun 19, 2012 | none ahead |
| Viatrisits history only | 20 open or running | phase 1since Sep 7, 2005 | Sep 7, 2005 | none ahead |
| Adapt Produtos Oftalmológicos Ltda.its history only | 10 open or running | phase 3since Mar 22, 2011 | Mar 22, 2011 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 10 open or running | phase 1since Dec 18, 2014 | Dec 18, 2014 | none ahead |
| Intarcia Therapeuticsits history only | 10 open or running | phase 1since Jan 1, 2016 | Jan 1, 2016 | none ahead |
| Jason Ahee, M.D.its history only | 11 open or running | phase 3since Aug 4, 2017 | Aug 4, 2017 | Oct 2030phase 3 · NCT03244072 |
| Research Insightits history only | 10 open or running | phase 4since Dec 18, 2019 | Dec 18, 2019 | none ahead |
| Richmond Research Instituteits history only | 10 open or running | phase 1since Nov 8, 2013 | Nov 8, 2013 | none ahead |
Also a collaborator on its studies: AbbVie, Parexel, Bristol-Myers Squibb, Topical Solutions and Shionogi.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Alcon only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 4, 2006First study: phase 4 study in Conjunctivitis, BacterialFirst studyNCT00312338 · 137 enrolled · United States
- Dec 19, 20072 phase 3 studies in Otitis MediaNCT00579189, NCT00578474
- Dec 19, 20072 phase 2 studiesNCT00579020, NCT00578773
- Sep 8, 2008Phase 3 study in Otitis ExternaNCT00750633 · 990 enrolled
- Sep 26, 2008Phase 4 study in CataractNCT00870103 · 64 enrolled · United States
- Nov 25, 2008Phase 4 study in Conjunctivitis, BacterialNCT00798577 · 24 enrolled · United States
- Feb 9, 2009Phase 4 study in CataractNCT00840580 · 79 enrolled · Korea, Republic of
- Feb 18, 2010Phase 3 study in Otitis MediaNCT01071902 · 400 enrolled · United States
- Nov 9, 2010Phase 2 study in Conjunctivitis, BacterialNCT01238783
- Jan 19, 2012Phase 3 study in CataractNCT01515826
- Apr 6, 2012Phase 3 study in Conjunctivitis, BacterialNCT01573910 · 985 enrolled · China
- May 20, 2013Phase 4 study in CataractNCT01859702 · 36 enrolled
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Topoisomerase IV inhibitor; Bacterial DNA gyrase inhibitor”ChEMBL 37, by rule
Studies
All 14 Alcon leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01859702Cataract | 4 | Completed | Aug 2012 | 36 |
| NCT01573910Conjunctivitis, Bacterial · China | 3 | Completed | Apr 2014 | 985 |
| NCT01515826Cataract | 3 | Withdrawn | Oct 2014 | 0 |
| NCT01238783Conjunctivitis, Bacterial | 2 | Withdrawn | Dec 2011 | 0 |
| NCT01071902Otitis Media · United States | 3 | Terminated | Oct 2011 | 400 |
| NCT00840580Cataract · Korea, Republic of | 4 | Completed | Sep 2009 | 79 |
| NCT00798577Conjunctivitis, Bacterial · United States | 4 | Completed | Feb 2009 | 24 |
| NCT00870103Cataract · United States | 4 | Completed | Feb 2009 | 64 |
| NCT00750633Otitis Externa | 3 | Completed | Jan 2009 | 990 |
| NCT00579189Otitis Media | 3 | Completed | Jan 2009 | 776 |
| NCT00579020Corneal Diseases · United States | 2 | Terminated | Feb 2009 | 144 |
| NCT00578773Otitis Media | 2 | Completed | Jan 2009 | 303 |
| NCT00578474Otitis Media | 3 | Completed | Aug 2008 | 911 |
| NCT00312338Conjunctivitis, Bacterial · United States | 4 | Completed | Jun 2007 | 137 |
How it is read
Names in the registry
- “Moxifloxacin”, 32 entries
- “Avelox (Moxifloxacin, BAY12-8039)”, 11 entries
- “Moxifloxacin (Avelox, BAY12-8039)”, 9 entries
- “moxifloxacin”, 6 entries
- “Moxidex otic solution”, 5 entries
Conditions, from the studies’ own filings
- Cataract, 6 studies
- Conjunctivitis, Bacterial, 5 studies
- Otitis Media, 4 studies
- Sinusitis, 3 studies
- Community-Acquired Pneumonia, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.